MAP2 and amyotrophic lateral sclerosis: Three ISO-treated types of ALS MNs showed higher levels of pSer65-Ub than untreated controls (Fig. 5A,B), as well as increased co-localization of LAMP2 and MTCO2 in MAP2+ MNs (Fig. 5C,D).